Access to anti-retroviral drugs, male in Yemen

Yemen: Access to anti-retroviral drugs, male was 27.0% in 2024. ◆ Volatile

Latest (2024)
27.0%
Change on year
up 3.8%
World rank
136th
of 141 countries
All-time high
27.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Yemen, 2000–2024

01020302000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 0 %2007: 1 %2008: 3 %2009: 4 %2010: 6 %2011: 7 %2012: 8 %2013: 9 %2014: 12 %2015: 13 %2016: 16 %2017: 17 %2018: 19 %2019: 20 %2020: 21 %2021: 22 %2022: 24 %2023: 26 %2024: 27 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Yemen is 27.0%, measured in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 3.8% on the previous year and up 125.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Yemen peaked at 27.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Yemen 136th out of 141 countries with data for 2024, putting it in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Yemen, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Yemen, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 0.0%
2007 1.0%
2008 3.0% +200.0%
2009 4.0% +33.3%
2010 6.0% +50.0%
2011 7.0% +16.7%
2012 8.0% +14.3%
2013 9.0% +12.5%
2014 12.0% +33.3%
2015 13.0% +8.3%
2016 16.0% +23.1%
2017 17.0% +6.2%
2018 19.0% +11.8%
2019 20.0% +5.3%
2020 21.0% +5.0%
2021 22.0% +4.8%
2022 24.0% +9.1%
2023 26.0% +8.3%
2024 27.0% +3.8%

Averages by decade

DecadeAverage LowestHighest Years
2000s 0.8% 0.0% 4.0% 10
2010s 12.7% 6.0% 20.0% 10
2020s 24.0% 21.0% 27.0% 5

Countries ranked near Yemen

  1. 133 Djibouti 28.0% compare
  2. 133 Fiji 28.0% compare
  3. 133 Tunisia 28.0% compare
  4. 136 Gambia 27.0% compare
  5. 138 Sudan 23.0% compare
  6. 139 Madagascar 22.0% compare

See the full ranking of 160 places →

More gender data for Yemen

All data for Yemen →

Frequently asked questions

What is access to anti-retroviral drugs, male in Yemen?
Access to anti-retroviral drugs, male in Yemen was 27.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Yemen?
The highest recorded value was 27.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Yemen?
The lowest recorded value was 0.0% in 2000.
How does Yemen rank for access to anti-retroviral drugs, male?
Yemen ranks 136th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Yemen?
Over the last ten years it is up 125.0%. The long-run trend across the full record is volatile.
Where does this Yemen data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Yemen. Statizoid, drawing on UNAIDS estimates. Retrieved 12 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/yemen-rep/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/yemen-rep/">Access to anti-retroviral drugs, male in Yemen</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.